ESC Congress 2024 — FINEARTS-HF shows finerenone reduces cardiovascular death and total of worsening heart failure (HF) events over median follow-up of 32 months.

Host, Dr Harriette Van Spall (McMaster University, CA) is joined by Principal investigator, Dr Scott Solomon (Brigham And Women's Hospital & Harvard Medical School, US) to discuss findings from the landmark FINEARTS-HF trial (NCT04435626; Bayer).

A multicenter, randomized, double-blind, placebo-controlled trial assessed the efficacy and safety of finerenone in 6016 patients with heart failure (NYHA class II-IV) and preserved left ventricular ejection fraction (LVEF ≥ 40%). The study, conducted across 660 sites in the United States, evaluated the impact of finerenone on the composite endpoint of cardiovascular death and heart failure events over a 42-month follow-up period.

Finerenone significantly reduced the risk of cardiovascular death, total heart failure events, and improved overall health status in patients with heart failure and mildly reduced or preserved ejection fraction. These benefits were observed across various subgroups, including those with different LVEF and those taking SGLT2 inhibitors. While hyperkalemia was more common, hypokalemia was less common in patients receiving finerenone.

Recorded on-site at ESC 2024, London.

Editors: Jordan Rance and Mirjam Boros.
Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David-Ben-Harosh.

Support: This is an independent interview produced by Radcliffe Cardiology.